N/A N=60 Diagnostic

Evaluation of 19-gauge vs 21-gauge EBUS TBNA in Assessing Thoracic Lymphadenopathy

Enlarged Lymph Nodes (Excluding Infective)

Bottom Line

View on ClinicalTrials.gov: NCT03657849 ↗

Enrolled (actual)

Serious AEs

5.0%

Results posted

Mar 2023

Primary outcome: Primary: Diagnostic Yield — 69; 68; 57; 57 lymph nodes

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: EBUS TBNA (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: HealthPartners Institute
Primary completion: Jan 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Diagnostic Yield	126; 125	—
PRIMARY Diagnostic Yield	126; 125	—

Summary

This study compares the yield of 19-gauge needles vs 21-gauge needles during EBUS TBNA procedures.

Eligibility Criteria

Inclusion Criteria

Age 18 years or older
Able to provide informed consent
Referred for EBUS TBNA sampling at Regions Hospital

Exclusion Criteria

On therapeutic warfarin, Plavix, or ticagrelor in the past 5 days
INR>1.8 or platelets <50K

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03657849). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.